allogeneic bone-marrow-derived clonal mesenchymal stem cell (hcMSC)

Class

allogeneic bone-marrow-derived clonal mesenchymal stem cell (hcMSC) therapy, IV infusion (SCM Lifescience)

Pathway

MSC-mediated immunoregulation dampening type-2 inflammatory responses in atopic dermatitis

Notes

original target text: allogeneic bone-marrow-derived clonal mesenchymal stem cell (hcMSC) therapy, IV infusion (SCM Lifescience)

Mesenchymal stem cells (MSCs) are multipotent cells, most commonly isolated from bone marrow, that do not primarily work by replacing damaged tissue but by signaling to the immune system. This therapy uses an allogeneic (donor-derived) clonal MSC line, expanded from a single cell to give a consistent, well-characterized cell population, and delivers it by intravenous infusion. The biological rationale rests on the well-documented capacity of MSCs to secrete immunoregulatory factors that dampen excessive immune activity. In atopic dermatitis, skin inflammation is driven substantially by a type-2 immune response, characterized by T-helper-2 (Th2) cells, cytokines such as interleukin-4 and interleukin-13, elevated immunoglobulin E, and activated mast cells and eosinophils, all of which contribute to itch, redness, and barrier breakdown. By modulating this axis rather than targeting a single cytokine or receptor, MSC therapy aims to recalibrate the broader inflammatory environment. This immunoregulatory mechanism is of interest across a range of inflammatory and autoimmune conditions beyond atopic dermatitis, wherever type-2 or other dysregulated immune responses drive disease.